Dr. Christina Vallgren
PhD in Applied Physics (Chalmers University of Technology, Sweden/CERN). MSc in Applied Physics and Nuclear Engineering (Chalmers University of Technology, Sweden). MBA. PMI. Staff Physicist at CERN 12+ years. Before coming to CERN, Christina earned an MSc degree in nuclear physics from Chalmers University of Technology, Sweden and did her master thesis in evaluation and study of control rods performance in various nuclear power plants. The work was carried out at Westinghouse, Sweden and KKL, nuclear power plant in Leibstadt, Switzerland. In 2008 she joined CERN for a PhD in applied physics and has worked there for the last 12 years. Christina was the main responsible for the LHC (Large Hadron Collider, 27 km, the world’s biggest accelerator) Beam Vacuum (the world’s biggest vacuum system) Operation and has also been the supervisor for five master students and two fellows. She is also a scientific journal referee for IEEE Transactions on Nuclear Science.
Dr. Marcus Palm
PhD in Applied Physics (Vienna University of Technology, Austria/CERN). MSc in Applied Physics and Electrical Engineering (Linköping University, Sweden). Detector Physicist at CERN 13 years: expertise in hadron therapy design, commissioning, CE-certification of medical devices, development of high performance detector systems, various detection technologies and data analysis. Marcus earned an MSc degree in Applied Physics and Electrical Engineering from Linköping University, Sweden. He joined CERN in 2006 and carried out his master thesis in design, implementation and operation of diamond detectors and electron multipliers for a novel kind of neutrino factory. During 2008-2011, he did a PhD at MedAustron/CERN on performance requirement of the entire beam delivery system from the accelerator to the patient, and translated clinical requirements on dose quality into hardware specifications on different elements. Directly after his PhD, Marcus continued at MedAustron as Systems Engineer in the Medical Frontend-group. He was then responsible for the system architecture of different patient safety systems and subsystem integration. Later, he was also working on system validation of the entire facility as a single medical device, for CE-certification. Before the creation of Terapet, he was the main responsible for two light-based detectors in the Large Hadron Collider (LHC) at CERN.
Prof. Raymond Miralbell, M.D. Ph.D.
Medical director at Centro de Protonterapia of Quirónsalud, Madrid, Spain, since 2019. Chairman of Servei de Radiooncologia at Institut Oncològic Teknon of Quironsalud, Barcelona, Spain. Chairman and Associated Professor of the Radiation Oncology Division, at the University Hospitals of Geneva (Switzerland) 2006-2019. Chairman of the Swiss Proton Users Group 2000 - 2008. Radiation oncologist trained from 1979 through 1989 in the University of Barcelona and the University of Harvard. Main research domain: Prostate cancer, breast cancer, proton therapy. - Imaging for radiotherapy treatment planning - Treatment precision optimization through image guided radiotherapy - Tracing of the biochemical relapse after curative surgery or radiotherapy - Prognostic value of hypoxic markers (pathological and imaging) - Quality of life studies in fragile patients on androgen deprivation - Biological modeling of prostate cancer response to irradiation and fractionation sensitivity. - Biological modeling for salvage radiotherapy after post-irradiation local failure - Stereo-tactic beam radiotherapy for prostate, gynecologic, ocular/orbital, and oligometastatic tumors.
Project Manager with in depth knowledge of quality assurance systems for medical devices (ISO 13485), risk analysis (ISO 14971) and software life cycle (IEC 62304). Founder of FilFla (BE). Expertise: Successful design, development, FAT/SAT and CE-certification of an operating ion beam therapy facility. Electronic design and development.
Dr. Ben Brunt
PhD in Particle Physics (University of Cambridge, UK), MPhys in Physics (University of Oxford, UK). Before joining Terapet, Ben held a CIO (Chief Information Officer) position at Milkalyser Ltd, a biotech start-up based in Exeter, UK. At Milkalyser, Ben led the lab and field validation of the company's automated hormone analysis system. Milkalyser was acquired by Lely NV in January 2020. Following the acquisition, Ben acted as the technical contact between the Exeter development team and the parent company. In 2018, Ben completed a PhD at the University of Cambridge, focusing on the analysis of data from the ATLAS detector at the Large Hadron Collider (LHC at CERN) in search of exotic physics processes.
Board of Directors
Former founding CEO of Kuros, a successful biotech/medtech entrepreneur who has brought his own start-ups from idea to IPO and is currently acting as chairman of the board at several other successful Swiss start-ups.
Director of Fongit (Switzerland's premier innovation incubator), a successful entrepreneur who is currently acting as board of director at several successful start-ups.
Prof. Rolf Lewensohn, M.D. Ph.D.
Prof. Rolf Lewensohn, M.D., Ph.D. serves as Senior Consultant at the department of Oncology, Karolinska University Hospital. Prof. Lewensohn is the Founder of Oncopeptides AB. He has a scientific background in DNA repair and apoptotic signaling in cancer, related to cancer therapy. He has published over 110 scientific publications within the cancer field. He serves as a Director of Karolinska Clinical Biomics Centre. He serves as a member of the scientific board of several funding bodies e.g. the Swedish Cancer Society, the Stockholm Cancer Society and King Gustav V’s Jubilee fund.
Serial entrepreneur with 15+ years of experience. Currently CEO and founder of Eliq AB (a software company that helps utilities to engage their customers by providing rich energy insights tools to consumers. The company is based between Gothenburg, Sweden and London, UK.). Founder of Acosense (acoustic spectroscopy sensor technology). Expertise: Business development, market strategy
Serial entrepreneur with 15+ years of experience. Currently CTO and founder of Minalyze AB. Minalyze AB was founded in 2009 in Gothenburg, Sweden and is the world leader in XRF core scanning instruments and software for visualization of geological data. The company is based both in Sweden and Australia today. Expertise: Business development in HighTech, market strategy
Founder team: Prof. Raymond Miralbell (left), Dr. Christina Vallgren (middle) and Dr. Marcus Palm (right).